Evidence map›Paper›PMID 38039595›Full record

ArticleEpidemics2023

Variation in pneumococcal invasiveness metrics is driven by serotype carriage duration and initial risk of disease.

Benjamin J Metcalf, Kristofer Wollein Waldetoft, Bernard W Beall, Sam P Brown

Open access · goldAbstract read
In one paragraph

Article in Epidemics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Invasive pneumococcal disease surveillance in Canada, 2023.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Non-invasiveEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Benjamin J MetcalfSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia; Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia; Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: ycm6@cdc.gov.
Kristofer Wollein WaldetoftSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia; Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia; Torsby Hospital, Torsby, Sweden.
Bernard W BeallCenters for Disease Control and Prevention, Atlanta, Georgia.
Sam P BrownSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia; Center for Microbial Dynamics and Infection, Georgia Institute of Technology, Atlanta, Georgia. Electronic address: sam.brown@biology.gatech.edu.
Centers for Disease Control and Prevention · USGeorgia Institute of Technology · US

Funding

Phages as drivers of pathogenicity: selective impacts and molecular targets of clinical Pseudomonas aeruginosa phagesR21AI143296 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI BROWN, SAMUEL PAUL, WHITELEY, MARVIN · 2019 to 2020
$434k
Building re-usable phage and antibiotic treatments via exploitation of bacteria-phage co-evolutionary dynamicsR21AI156817 · NIAID · GEORGIA INSTITUTE OF TECHNOLOGY · PI BROWN, SAMUEL PAUL · 2021 to 2022
$434k
Intramural CDC HHS CC999999NIAID NIH HHS R21 AI143296NIAID NIH HHS R21 AI156817
6 · The paper itself

Abstract

Streptococcus pneumoniae is an opportunistic pathogen that, while usually carried asymptomatically, can cause severe invasive diseases like meningitis and bacteremic pneumonia. A central goal in S. pneumoniae public health management is to identify which serotypes (immunologically distinct strains) pose the most risk of invasive disease. The most common invasiveness metrics use cross-sectional data (i.e., invasive odds ratios (IOR)), or longitudinal data (i.e., attack rates (AR)). To assess the reliability of these metrics we developed an epidemiological model of carriage and invasive disease. Our mathematical analyses illustrate qualitative failures with the IOR metric (e.g., IOR can decline with increasing invasiveness parameters). Fitting the model to both longitudinal and cross-sectional data, our analysis supports previous work indicating that invasion risk is maximal at or near time of colonization. This pattern of early invasive disease risk leads to substantial (up to 5-fold) biases when estimating underlying differences in invasiveness from IOR metrics, due to the impact of carriage duration on IOR. Together, these results raise serious concerns with the IOR metric as a basis for public health decision-making and lend support for multiple alternate metrics including AR.

Indexed as

Pneumococcal InfectionsStreptococcus pneumoniaeCarrier StateCross-Sectional StudiesHumansInfantNasopharynxPneumococcal VaccinesReproducibility of ResultsSerogroupPneumococcal VaccinesCarriage durationCompartmental modelInvasive diseaseStreptococcus pneumoniaeVirulence

Identifiers

PMID38039595
PMCPMC10786323
OpenAlexW4388905656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.